Home > Insider Trading > Filing (0001415889-24-022987)

Filing Details

Accession Number:: 0001415889-24-022987
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-09-05 19:51:04
Reporting Period:: 2024-09-03

Accepted Time:: 2024-09-05 19:51:04
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1620463	Athira Pharma Inc.	ATHA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1563623	Andrew Gengos	C/O Athira Pharma, Inc. 18706 North Creek Parkway, Suite 104 Bothell WA 98011	Cfo And Chief Business Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-05-20	10,000	$1.34	93,804	No	5	A	Direct
Common Stock	Acquisiton	2024-09-03	5,000	$0.00	98,804	No	4	A	Direct
Common Stock	Disposition	2024-09-05	1,272	$0.57	97,532	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	5	A	Direct
No	4	A	Direct
No	4	S	Direct

Footnotes

The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of November 20, 2023 through May 20, 2024. This transaction is exempt under Rule 16b-3(c).
The Purchase Period ended May 20, 2024 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 20, 2023.
In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 20, 2023.
On May 18, 2023, the reporting person was granted restricted stock units ("RSUs") representing 10,000 shares of Common Stock of the Issuer. The RSUs were scheduled to vest according to the following amended schedule: (1) fifty percent (50%) of the shares subject to the RSU award vest as of the date the the Compensation Committee (the "Committee" determines that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial has been completed, and (2) the remaining fifty percent (50%) of the shares subject to the RSUs shall vest at the completion of the public readout of topline results of the Company's LIFT-AD Phase 2/3 clinical trial, in each case subject to continued service with the Issuer through the applicable vesting date.
On September 3, 2024, the Company completed the public readout of the topline results of its LIFT-AD Phase 2/3 clinical trial and 5,000 RSUs vested on such date.
Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of RSUs pursuant to mandatory "sell to cover" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person.
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $0.5505 to $0.5751, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.